CONBRIZA Receives Positive CHMP Opinion For The Treatment Of Postmenopausal Osteoporosis In Women At Increased Risk Of Fracture

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. CONBRIZA, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

More: continued here

Filed under: Bones on February 25th, 2009